RESUMO
Streptococcus uberis is one of the most prevalent pathogens causing clinical and subclinical mastitis worldwide. Among bacterial factors involved in intramammary infections caused by this organism, S. uberis adhesion molecule (SUAM) is one of the main virulence factors identified. This molecule is involved in S. uberis internalization to mammary epithelial cells through lactoferrin (Lf) binding. The objective of this study was to evaluate SUAM properties as a potential subunit vaccine component for prevention of S. uberis mastitis. B epitope prediction analysis of SUAM sequence was used to identify potentially immunogenic regions. Since these regions were detected all along the gene, this criterion did not allow selecting a specific region as a potential immunogen. Hence, four fractions of SUAM (-1fr, 2fr, 3fr and 4fr), comprising most of the protein, were cloned and expressed. Every fraction elicited a humoral immune response in mice as predicted by bioinformatics analysis. SUAM-1fr generated antibodies with the highest recognition ability towards SUAM native protein. Moreover, antibodies against SUAM-1fr produced the highest proportion of internalization inhibition of S. uberis to mammary epithelial cells. In conclusion, SUAM immunogenic and functionally relevant regions were identified and allowed to propose SUAM-1fr as a potential candidate for a subunit vaccine for S. uberis mastitis prevention.
Assuntos
Aderência Bacteriana/imunologia , Vacinas Bacterianas/imunologia , Mastite/prevenção & controle , Streptococcus/imunologia , Sequência de Aminoácidos , Animais , Anticorpos Antibacterianos/sangue , Aderência Bacteriana/genética , Proteínas de Bactérias/genética , Proteínas de Bactérias/imunologia , Vacinas Bacterianas/genética , Sequência de Bases , Bovinos , DNA Bacteriano/genética , Células Epiteliais/imunologia , Células Epiteliais/microbiologia , Feminino , Imunoglobulina G/sangue , Lactoferrina/metabolismo , Camundongos , Modelos Animais , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Infecções Estreptocócicas/microbiologia , Streptococcus/genética , Vacinas de Subunidades Antigênicas/biossíntese , Vacinas de Subunidades Antigênicas/genética , Vacinas de Subunidades Antigênicas/imunologia , Fatores de Virulência/genéticaRESUMO
Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.
Assuntos
Anticorpos Monoclonais/biossíntese , Formação de Anticorpos , Nicotiana/metabolismo , Doença de Alzheimer/imunologia , Peptídeos beta-Amiloides/imunologia , Animais , Doenças Autoimunes/tratamento farmacológico , Produtos Biológicos/biossíntese , Guerra Biológica/prevenção & controle , Comércio , Doenças Transmissíveis Emergentes/imunologia , Doenças Transmissíveis Emergentes/prevenção & controle , Anticoncepção/métodos , Glicosilação , Humanos , Imunoglobulina G/uso terapêutico , Imunoglobulinas Intravenosas/uso terapêutico , Inflamação/tratamento farmacológico , Camundongos , Polissacarídeos/biossíntese , Gravidez não Planejada , Infecções por Vírus Respiratório Sincicial/economia , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Vírus Sinciciais Respiratórios/imunologia , Infecções Sexualmente Transmissíveis/prevenção & controle , Nicotiana/imunologia , Vacinas de Subunidades Antigênicas/biossínteseRESUMO
Recombinant subunit vaccines have been with us for the last 30 years and they provide us with the unique opportunity to choose from the many available production systems that can be used for recombinant protein expression. Plants have become an attractive production platform for recombinant biopharmaceuticals and vaccines have been at the forefront of this new and expanding industry sector. The particular advantages of plant-based vaccines in terms of cost, safety and scalability are discussed in the light of recent successful clinical trials and the likely impact of plant systems on the vaccine industry is evaluated.
Assuntos
Plantas/metabolismo , Vacinas de Subunidades Antigênicas/biossíntese , Vacinas Sintéticas/biossíntese , Humanos , Plantas/genética , Estados Unidos , Vacinas de Subunidades Antigênicas/efeitos adversos , Vacinas de Subunidades Antigênicas/economia , Vacinas de Subunidades Antigênicas/genética , Vacinas Sintéticas/efeitos adversos , Vacinas Sintéticas/economia , Vacinas Sintéticas/genéticaRESUMO
Cell substrates are a key component of successful vaccine development and throughout the last several decades there has been a dramatic increase in the types of cells available for vaccine production. Nevertheless, there is a continued demand for new and innovative approaches for vaccine development and manufacturing. Recent developments involving cells of insect and plant origin are attracting considerable scientific interest. Here we review vaccine antigen production in plant-based systems as was presented by Dr. Vidadi Yusibov of Fraunhofer USA Center for Molecular Biotechnology at the IABS International Scientific Workshop on NEW CELLS FOR NEW VACCINES II that was held in Wilmington, Delaware on September 17-19, 2007.